1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology
  4. > Biopharmaceutical Market Trends
Global Spinal Muscular Atrophy Market: Industry Analysis & Outlook (2019-2026)

Global Spinal Muscular Atrophy Market: Industry Analysis & Outlook (2019-2026)

  • February 2019
  • 72 pages
  • ID: 5748375
  • Format: PDF
  • By Koncept Analytics

Summary

Table of Contents

Search Inside

Spinal Muscular Atrophy (SMA) is a form of neuromuscular disease that results in loss of lower motor neurons and progressive muscle wasting, often leading to early death.

Presently, it affects about 1 in 11,000 babies and about 1 in every 50 Americans is the disease carrier. On the basis of either the onset age of symptoms, SMA is classified into Type I, Type II, Type III and Type IV diseases.

Currently, no specific therapies for cure exist, but certain speciality drugs are expected to enter the market in the year 2019. The clinical care differs with the severity or type of the disorder category.

The global market is expected to witness a lucrative growth due the rising pharmaceuticals research and development (R&D) expenditures, increasing personal healthcare expenditure, accelerating economic growth and growing spinal muscular atrophy occurrence. The market is trending with progressing drug pipeline and high preference for gene therapy. However, there are some growth hindering factors in the market including lethargic drug approval process and associated business risks.

Regionally, the U.S. is expected to hold the leading position in the market, due to the increasing prevalence of motor neuron disorders in the population along with high preference of genetic correction therapy and myostatin drugs.

“Global Spinal Muscular Atrophy Market: Industry Analysis & Outlook (2019-2026)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. Key players i.e. Biogen Inc., Novartis International AG, Roche Holding AG and Cytokinetics, Inc are being profiled along with their respective financials and growth strategies.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Dystrophin (DMD) - Pipeline Review, H2 2019

Dystrophin (DMD) - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Dystrophin (DMD) - Pipeline Review, H2 2019SummaryDystrophin (DMD) - Dystrophin is a cytoplasmic protein. It anchors the extracellular matrix to the cytoskeleton via F-actin. It acts as ligand for dystroglycan. ...

Metachromatic Leukodystrophy (MLD) - Pipeline Review, H2 2019

Metachromatic Leukodystrophy (MLD) - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Metachromatic Leukodystrophy (MLD) - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Metachromatic Leukodystrophy - Pipeline Review, H2 2019, provides an ...

N Sulphoglucosamine Sulphohydrolase - Pipeline Review, H2 2019

N Sulphoglucosamine Sulphohydrolase - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

N Sulphoglucosamine Sulphohydrolase - Pipeline Review, H2 2019SummaryN Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) pipeline Target constitutes ...


ref:plp2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on